1. Home
  2. Analysis
  3. Strattera
  4. Qsymia

Strattera and Qsymia drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 19 people who take Strattera and Qsymia. Common interactions include pain among females, and anhedonia among males.

The phase IV clinical study analyzes what interactions people who take Strattera and Qsymia have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 28, 2023

19 people who take Strattera and Qsymia together, and have interactions are studied.

What is Strattera?

Strattera has active ingredients of atomoxetine hydrochloride. It is used in attention deficit hyperactivity disorder. Currently, eHealthMe is studying from 28,949 Strattera users.

What is Qsymia?

Qsymia has active ingredients of phentermine hydrochloride; topiramate. It is used in weight loss. Currently, eHealthMe is studying from 3,726 Qsymia users.

Number of Strattera and Qsymia reports submitted per year:

Strattera and Qsymia drug interactions.

Common Strattera and Qsymia drug interactions by gender *:

female:

  1. Pain
  2. Drug hypersensitivity
  3. Dyspnoea
  4. Bronchitis
  5. Choking
  6. Hypoaesthesia
  7. Lip swelling
  8. Pyrexia
  9. Swelling face
  10. Swollen tongue

male:

  1. Anhedonia
  2. Anxiety
  3. Renal impairment
  4. Bone density decreased
  5. Bone pain
  6. Chronic kidney disease
  7. Drug resistance
  8. Emotional distress
  9. Fanconi syndrome acquired
  10. Gait disturbance

Common Strattera and Qsymia drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Drug hypersensitivity
  2. Pain
  3. Dyspnoea
  4. Bronchitis
  5. Choking
  6. Hypoaesthesia
  7. Lip swelling
  8. Pyrexia
  9. Swelling face
  10. Swollen tongue

30-39:

n/a

40-49:

  1. Anhedonia
  2. Anxiety
  3. Renal impairment
  4. Burning sensation mucosal
  5. Paraesthesia oral
  6. Bone density decreased
  7. Bone pain
  8. Chronic kidney disease
  9. Drug resistance
  10. Emotional distress

50-59:

n/a

60+:

n/a

Common conditions people have *:

  1. Insomnia (sleeplessness): 14 people, 73.68%
  2. Weight Decreased: 2 people, 10.53%
  3. Hiv Infection: 2 people, 10.53%
  4. Type 2 Diabetes: 1 person, 5.26%
  5. Sleep Disorder: 1 person, 5.26%
  6. Osteoporosis (bones weak and more likely to break): 1 person, 5.26%
  7. Hypersensitivity: 1 person, 5.26%
  8. High Blood Cholesterol: 1 person, 5.26%
  9. Cardiac Murmur (an heart sound in valve abnormality): 1 person, 5.26%
  10. Asthma: 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Strattera and Qsymia?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Common Strattera drug interactions:

Browse interactions between Strattera and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Qsymia drug interactions:

Browse interactions between Qsymia and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on atomoxetine hydrochloride and phentermine hydrochloride; topiramate (the active ingredients of Strattera and Qsymia, respectively), and Strattera and Qsymia (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Strattera and Qsymia.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.